Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
Status:
Completed
Trial end date:
2018-08-13
Target enrollment:
Participant gender:
Summary
This study is conducted in Europe. The aim of the study is to compare the effect of
semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg
once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes.
The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at
the clinic and 3 phone calls with the study doctor. At the visits, participants will have a
number of tests, for example: general health checks, blood samples, heart and eye checks etc.
Participants will also fill in some forms about their health and satisfaction with their
diabetes treatment.